m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05918
 [1]
Non-coding RNA circABCC4 IGF2BP2  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CCAR1 CCAR1 IGF2BP2 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) READER
 Regulator Info 
m6A Target Cell division cycle and apoptosis regulator protein 1 (CCAR1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_ABCC4 circRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary METTL3 overexpression increased Circ_ABCC4 expression via m6A modification in PCa cells. circABCC4 recruited IGF2BP2 protein to Cell division cycle and apoptosis regulator protein 1 (CCAR1) mRNA, thereby enhancing CCAR1 mRNA stability and subsequent activation of the Wnt/beta-catenin pathway.
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
Pathway Response Wnt signaling pathway hsa04310
Cell Process Cell migration, Cell invasion
Cell metastasis
Cell proliferation
In-vitro Model
 RWPE-1 Normal Homo sapiens CVCL_3791
DU145 Prostate carcinoma Homo sapiens CVCL_0105
PC-3 Prostate carcinoma Homo sapiens CVCL_0035
LNCaP Prostate carcinoma Homo sapiens CVCL_0395
22Rv1 Prostate carcinoma Homo sapiens CVCL_1045
VCaP Prostate carcinoma Homo sapiens CVCL_2235
In-vivo Model DU145 and PC-3 cells (2 × 106) stably transfected with shMETTL3, shcircABCC4 or sh-NC were subcutaneously injected into the male eight-week-old BALB/c nude mice (16-20 g, Hunan Slac Jingda Laboratory Animal Co., Ltd).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C82: Prostate cancer 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name CC-94676 Phase 1 [2]
External Link
TTD: DNY63Z
References
Ref 1 m6A-modified circABCC4 promotes stemness and metastasis of prostate cancer by recruiting IGF2BP2 to increase stability of CCAR1. Cancer Gene Ther. 2023 Oct;30(10):1426-1440. doi: 10.1038/s41417-023-00650-x. Epub 2023 Aug 10.
Ref 2 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.